Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Concepts

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 May 16

PMID 37190213

Authors

Katrin S Kurz

Michaela Ott

Sabrina Kalmbach

Sophia Steinlein

Claudia Kalla

Heike Horn

German Ott

Annette M Staiger

Affiliations

Soon will be listed here.

Abstract

The family/class of the large B-cell lymphomas (LBCL) in the 5th edition of the World Health Organization (WHO) classification of haematolymphoid tumors (WHO-HAEM5) features only a few major changes as compared to the 4th edition. In most entities, there are only subtle changes, many of them only representing some minor modifications in diagnostic terms. Major changes have been made in the diffuse large B-cell lymphomas (DLBCL)/high-grade B-cell lymphomas (HGBL) associated with and and/or rearrangements. This category now consists of and rearranged cases exclusively, while the double hit lymphomas now constitute genetic subtypes of DLBCL, not otherwise specified (NOS) or of HGBL, NOS. Other major changes are the conceptual merger of lymphomas arising in immune-privileged sites and the description of LBCL arising in the setting of immune dysregulation/deficiency. In addition, novel findings concerning underlying biological mechanisms in the pathogenesis of the different entities are provided.

Citing Articles

Cutaneous manifestations as the presenting signs of diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

Pinero-Crespo G, Kucharik A, Chen W, Idiaquez D, Doenges J, Zhang Y JAAD Case Rep. 2025; 55():23-26.

PMID: 39790106 PMC: 11714132. DOI: 10.1016/j.jdcr.2024.09.032.

Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.

Masnikosa R, Cvetkovic Z, Piric D Int J Mol Sci. 2024; 25(21).

PMID: 39518937 PMC: 11545713. DOI: 10.3390/ijms252111384.

Clinicopathological and genetic analyses of thyroid large B-cell lymphoma in a Japanese population.

Numata A, Sakai R, Kawachi K, Ishiyama Y, Hattori Y, Takasaki H J Clin Exp Hematop. 2024; 64(4):286-291.

PMID: 39462546 PMC: 11786153. DOI: 10.3960/jslrt.24010.

CODOX-M/IVAC-R DA-EPOCH-R in double-hit/triple-hit lymphoma patients aged 60 years or under.

Atallah-Yunes S, Rees M, Witzig T, Habermann T, Munoz J, Iqbal M Haematologica. 2024; 110(2):448-456.

PMID: 39385736 PMC: 11788628. DOI: 10.3324/haematol.2024.286168.

Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data.

Bayly-McCredie E, Treisman M, Fiorenza S Int J Mol Sci. 2024; 25(17).

PMID: 39273684 PMC: 11396745. DOI: 10.3390/ijms25179736.

References

Ramis-Zaldivar J, Gonzalez-Farre B, Nicolae A, Pack S, Clot G, Nadeu F . MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021; 106(10):2682-2693. PMC: 8485662. DOI: 10.3324/haematol.2020.271957. View

Huttl K, Staiger A, Richter J, Ott M, Kalmbach S, Klapper W . The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS. Virchows Arch. 2021; 479(3):575-583. DOI: 10.1007/s00428-021-03050-4. View

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Krull J, Wenzl K, Hartert K, Manske M, Sarangi V, Maurer M . Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer J. 2020; 10(11):117. PMC: 7652824. DOI: 10.1038/s41408-020-00382-3. View

Sakamoto K, Nakasone H, Togashi Y, Sakata S, Tsuyama N, Baba S . ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. Int J Hematol. 2016; 103(4):399-408. DOI: 10.1007/s12185-016-1934-1. View

Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler O, Deckert M . Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood. 2003; 103(5):1869-75. DOI: 10.1182/blood-2003-05-1465. View

Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A . Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. Leukemia. 2016; 30(7):1568-79. DOI: 10.1038/leu.2016.67. View

Kasuya A, Fujiyama T, Shirahama S, Hashizume H, Tokura Y . Decreased expression of homeostatic chemokine receptors in intravascular large B-cell lymphoma. Eur J Dermatol. 2012; 22(2):272-3. DOI: 10.1684/ejd.2012.1639. View

Sha C, Barrans S, Cucco F, Bentley M, Care M, Cummin T . Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol. 2018; 37(3):202-212. PMC: 6338391. DOI: 10.1200/JCO.18.01314. View

10.

Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler O, Siebert R, Deckert M . Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011; 122(6):791-2. DOI: 10.1007/s00401-011-0891-2. View

11.

Schrader A, Jansen P, Vermeer M, Kleiverda J, Vermaat J, Willemze R . High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Am J Surg Pathol. 2018; 42(11):1488-1494. DOI: 10.1097/PAS.0000000000001132. View

12.

Schwindt H, Vater I, Kreuz M, Montesinos-Rongen M, Brunn A, Richter J . Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia. 2009; 23(10):1875-84. DOI: 10.1038/leu.2009.120. View

13.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

14.

Montes-Moreno S, Gonzalez-Medina A, Rodriguez-Pinilla S, Maestre L, Sanchez-Verde L, Roncador G . Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010; 95(8):1342-9. PMC: 2913083. DOI: 10.3324/haematol.2009.016113. View

15.

Vega F, Chang C, Medeiros L, Udden M, Cho-Vega J, Lau C . Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2004; 18(6):806-15. DOI: 10.1038/modpathol.3800355. View

16.

Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R . The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2014; 29(3):677-85. DOI: 10.1038/leu.2014.264. View

17.

Suehara Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, Itoh T, Kaji D . Liquid biopsy for the identification of intravascular large B-cell lymphoma. Haematologica. 2018; 103(6):e241-e244. PMC: 6058794. DOI: 10.3324/haematol.2017.178830. View

18.

Twa D, Chan F, Ben-Neriah S, Woolcock B, Mottok A, Tan K . Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014; 123(13):2062-5. DOI: 10.1182/blood-2013-10-535443. View

19.

Kinoshita M, Izumoto S, Hashimoto N, Kishima H, Kagawa N, Hashiba T . Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas. Brain Tumor Pathol. 2008; 25(2):73-8. DOI: 10.1007/s10014-008-0232-x. View

20.

Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot J . Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2008; 113(12):2765-3775. DOI: 10.1182/blood-2008-07-168096. View